An Oral Pill for Geographic Atrophy? What the Gildeuretinol Trial Results Showed
Gildeuretinol for Geographic Atrophy at a Glance
Not yet. Gildeuretinol is a daily capsule taken by mouth. It was tested in a study called SAGA. The study missed its main goal. Patches of atrophy grew a little more slowly on the capsule, but the gap was small enough that chance could explain it1. Some vision scores did favor the capsule. Those were back-up results that hint at a benefit rather than settle it. The medicines approved for geographic atrophy are two injections given into the eye, Syfovre and Izervay2, and gildeuretinol was taken by people enrolled in the SAGA trial, which compared the capsule against a placebo1. That is hard to hear, but there are still useful steps you can take now.
SAGA followed 198 people for two years. The atrophy patch grew about 1.62 square millimeters a year on the capsule and about 1.87 on placebo. That gap of about a quarter of a square millimeter did not reach the usual bar for a reliable finding1. The more interesting signal was in how people saw. On a dim-light eye chart, the capsule group lost about 3.9 letters over two years, against about 8.3 letters on placebo, and reported less decline in reading and in quality of life1. The authors called those findings exploratory.
This study does not change what is available to you today. Keep the appointments you already have. Geographic atrophy is checked with retinal imaging: an OCT scan gives detailed images of the retina to detect thinning areas, and fundus autofluorescence is a non-invasive way to look for abnormalities in the retina3. Ask your doctor about the two approved eye injections, which suit some people and not others. Keep checking each eye at home. If research interests you, ask your retina specialist what you might qualify for.
What Gildeuretinol Is and How It Is Meant to Work
Gildeuretinol, also called ALK-001, is not a supplement. It is vitamin A that chemists have deliberately altered. Hydrogen atoms at one spot on the vitamin A molecule are swapped for deuterium, a heavier but natural form of hydrogen4. The idea is that the body handles the molecule much as it handles ordinary vitamin A, while the heavier bond is harder to break at that one spot. That single change is the whole idea, and it is why a shop-bought vitamin A capsule is not a stand-in.
Your retina recycles vitamin A every time you see. The recycling is not perfect. Two vitamin A molecules can pair up into byproducts such as A2E. These collect as lipofuscin deposits in the retinal pigment epithelium, the support layer under the retina, and that buildup is a feature of macular degeneration and of Stargardt disease4. The theory is that slowing the pairing keeps that layer healthier. In laboratory tests the deuterium form paired up considerably more slowly than ordinary vitamin A, and giving it to normal rodents slowed the making of A2E4. Laboratory promise is a starting point, not proof of benefit in people.
The two approved medicines for this condition are injected into the eye, every month or every other month, on an ongoing basis2. The SYFOVRE label sets one injection into the affected eye every 25 to 60 days. The IZERVAY label sets one injection into the affected eye each month56. A capsule would reach both eyes, need no clinic visit, and avoid injection risks. That only matters if it works.
What the SAGA Trial Results Showed
It ran for 24 months at multiple centers. Adults aged 60 and older with geographic atrophy from macular degeneration were randomly assigned to the capsule or to a matching placebo, and neither they nor their doctors knew which they took7. 198 people took part, two on the capsule for every one on placebo. Their average age was about 78, about 69 of every 100 were women, and about 69 of every 100 finished both years1.
SAGA set out to answer one question: would the atrophy patch grow more slowly? The answer was a little, but not clearly. Patches grew about 1.62 square millimeters a year on the capsule and about 1.87 on placebo. The difference of about 0.25 square millimeters a year came with a P value of 0.075, just above the usual 0.05 mark, so it did not count as a positive result1. In plain terms, luck could not be ruled out. That miss is the headline of this trial.
The measures closest to daily life leaned the other way. Over two years the capsule group lost about 3.9 letters of low-luminance visual acuity, meaning sight measured on a dimmed chart, against about 8.3 letters on placebo. They lost about 6.9 letters on the standard chart against about 10.2, and reported smaller declines in quality of life and in reading independence1. Low-light sight and reading are what people with this condition say they miss most.
| Measured over 2 years | Gildeuretinol | Placebo |
|---|---|---|
| Atrophy patch growth each year | about 1.62 sq mm | about 1.87 sq mm |
| Letters lost, dim-light chart | about 3.9 | about 8.3 |
| Letters lost, standard chart | about 6.9 | about 10.2 |
A trial names its main question in advance so nobody can go fishing afterwards for whichever measure looked good. When that question comes back negative, the other measures are clues, not conclusions. The SAGA authors called the favorable secondary and reading findings exploratory, with nominal P values, and wrote that they support further evaluation in adequately powered trials1. That is a researcher's way of saying the idea earned another study, not a place in your medicine cabinet.
How Gildeuretinol Was Taken in the Studies
In SAGA, people took an oral capsule of the deuterated vitamin A daily for 24 months, or a placebo oral capsule on the same daily schedule7. There was no eye drop, no injection, and no infusion. The strength is set by the study protocol, not by you, because no approved dosing exists outside a trial. A study team supplies the capsules, the schedule and the safety checks together.
A drug still being tested is handed out by the study team under the trial protocol, not by a pharmacy. In SAGA, participants took the gildeuretinol capsule or a matching placebo capsule as part of the study7. The medicines approved for geographic atrophy are two injections given into the eye, Syfovre and Izervay2, so there is no capsule for this condition on a pharmacy shelf. If you see gildeuretinol offered for sale online, that is a warning sign rather than an opportunity, because anything sold that way has unverified contents and no safety oversight.
This part matters if you hoped to join a study. The registry record for SAGA, the geographic atrophy study, lists it as completed7. The gildeuretinol study now recruiting is a phase 3 trial in Stargardt disease, an inherited retinal condition8. Searching the registry for this drug turns up no gildeuretinol study in geographic atrophy that is open to enrollment9. So for now there is no open door to this capsule for someone with geographic atrophy. That can change, and your retina specialist usually hears early when a study opens nearby.
Side Effects Reported in the Gildeuretinol Trial
Most of what was recorded is the ordinary background of illness at this age, though a few laboratory shifts are worth naming. Among reports logged in at least about 5 of every 100 people in one of the groups, raised blood triglycerides appeared in 15 of 135 on the capsule against 5 of 63 on placebo, a raised alkaline phosphatase blood test in 10 of 135 against 5 of 63, a fall in 9 of 135 against 6 of 63, and joint pain in 7 of 135 against 3 of 637. Small counts show what was seen, not what the capsule caused.
| Reported during the 2-year study | Gildeuretinol (of 135) | Placebo (of 63) |
|---|---|---|
| Raised blood triglycerides | 15 | 5 |
| Raised alkaline phosphatase test | 10 | 5 |
| A fall | 9 | 6 |
| Joint pain | 7 | 3 |
| Any serious medical event | 26 | 14 |
| Death during the study | 5 | 1 |
These numbers deserve to be shown plainly. Serious medical events were logged in 26 of 135 people on the capsule and in 14 of 63 on placebo. Five of the 135 on the capsule and one of the 63 on placebo died during the study. The serious events listed are mainly heart and stroke events, infections and cancer diagnoses7. The serious-event share was similar in both groups. Counts this small cannot separate a real signal from ordinary variation, and a registry table is not a finding about cause.
Two years of data on about 135 people is a start, not a full safety picture. Nobody yet knows how this capsule behaves over five or ten years, how it sits with the long medicine lists many older adults carry, or whether the shifts in blood fats and liver-related tests matter over time. Those open questions are why the drug stays inside monitored studies rather than on a shelf.
Who Would Not Be a Fit for This Kind of Study
SAGA enrolled adults aged 60 and older who had geographic atrophy from dry macular degeneration in at least one eye. It excluded people whose other medical conditions could affect how the atrophy progressed, interfere with study procedures, or stop them completing the study7. In practice the atrophy has to be measurable on imaging, and other eye disease that clouds those images can rule someone out. Only a retina specialist can tell you where you stand.
This is the most important safety point on the page, because substituting seems so logical. Ordinary vitamin A is not deuterated, so it does not slow the chemical pairing this drug was built to slow4. Vitamin A beyond what you need also builds up in the body and can cause serious problems, and large doses in pregnancy can cause birth defects10. Supplements are regulated differently from medicines, which is why their labels carry this required statement: 'This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.' The AREDS and AREDS2 formulas were studied to slow intermediate AMD from becoming late AMD, and were never meant as a general vitamin A product11. Bring the question to your eye doctor instead.
If a study does open near you, a short list decides the conversation quickly, so have it ready. Bring every medicine and supplement bottle you take, including anything for cholesterol, since raised triglycerides were among the laboratory values logged more often in the capsule group7. Mention liver disease, kidney disease, a history of falls and any planned surgery, plus other eye conditions such as glaucoma or a past retinal detachment. None of this automatically shuts a door; it lets the study doctor judge safety honestly.
Risks, Realistic Expectations, and What Comes Next
The evidence supports the view that an oral approach to vitamin A byproducts deserves another, properly sized trial, with the functional measures as the main question next time. It does not support any claim that this capsule slows geographic atrophy, protects your reading, or belongs in your routine now. The published report is explicit that the primary endpoint was not met and that the favorable findings were exploratory1. Anyone offering more certainty is going beyond the data.
The approved options are what exists today. SYFOVRE and IZERVAY are both approved by the FDA for geographic atrophy from macular degeneration, and both are given by injection into the affected eye56. In trials they slowed lesion growth by roughly a seventh to a fifth. Neither has been shown to improve eyesight or restore lost vision, and reported harms include a turn to wet AMD and rare retinal vasculitis that can cause permanent vision loss2. That is a real trade-off, and reasonable people decide it differently.
Geographic atrophy takes central sight slowly, and it leaves a great deal behind. It thins the macula, the part of the retina that handles sharp central sight, so reading, faces and low-light seeing suffer first, and no therapy available today restores what has been lost3. Side vision is usually kept, and with it walking, orientation and much of daily independence. Magnifiers, strong task lighting, high-contrast screens and low-vision rehabilitation change how the remaining sight feels to use, and for most people they do more this year than any drug in development.
When to Contact Your Eye Doctor About Geographic Atrophy
Geographic atrophy changes slowly. A sudden change usually means something else, and that something is often fixable. Call your eye doctor right away, ideally within a day or two, if you notice any of these:
- Straight lines, such as door frames or text, suddenly look wavy or bent.
- A new dark or empty spot appears near the center of your sight.
- Sight in one eye drops noticeably over hours or days.
- Objects look smaller or warped in one eye but not the other.
Straight lines looking wavy is a known warning sign of late AMD and should send you to an eye doctor right away12, because the wet form of AMD responds to injections that block VEGF, which improve sight and lower the risk of vision loss13. The sooner that starts, the more sight there is to protect. This is a call, not a crisis. Most such calls end in reassurance, and the rest are exactly the ones worth catching early.
Between visits you are the early-warning system, and the check takes under a minute. Cover one eye and look at a fixed pattern, such as an Amsler grid or a window frame, then repeat with the other eye. Note any new wavy, missing or blurred area. Doing it at the same time each day makes small changes easier to spot. Your eye doctor follows the atrophy with retinal imaging: OCT to detect thinning areas, and fundus photography to capture images of the retina and track changes over time3.
The right specialist here is a retina specialist, an ophthalmologist with extra training in the back of the eye, alongside the optometrist or ophthalmologist you already see. Geographic atrophy is usually found after age 60 and affects roughly 8 million people worldwide, about 1 in 5 of everyone with AMD3, so retina clinics see it constantly. Ask directly whether you are a candidate for the approved injections, and what studies you would qualify for.
Common Questions About the Gildeuretinol Results
It missed its main goal, which is not the same as showing the drug does nothing. The study asked whether the atrophy patch would grow more slowly and found a small difference that chance could explain. Several secondary measures of how people saw and read favored the capsule. Researchers call that a signal worth another, larger study, not evidence of benefit. The fair verdict is unproven, with enough of a hint to keep the question open.
No. Off-label prescribing applies only to medicines already approved for some other use, and this one has no approval at all. It stays an investigational drug supplied inside registered studies, so there is no lawful pharmacy source for it. If a website or clinic offers to sell it, regard that as a red flag. The only legitimate route is a study, and none is open for this condition now.
No, and this is the most important distinction here. Gildeuretinol is vitamin A altered with deuterium at one position, which is what makes it resist the chemical pairing that produces retinal byproducts. Standard vitamin A has no such change, so taking large amounts of it will not copy the effect studied. Extra vitamin A instead builds up in the body and can cause serious problems. Raise the question with your eye doctor.
The injections exist today and carry regulatory approval for this condition; the capsule has neither. In trials the injections slowed lesion growth modestly, without being shown to improve sight, and they bring the burden and risks of repeated procedures inside the eye. The capsule is easier to take but did not clear its main bar. You are comparing a modest, available option that carries real risks against an open question.
Geographic atrophy grows slowly, so a shorter study cannot see a difference between groups. Two years is roughly the minimum needed to measure patch size reliably on imaging, which is why the approved injections were tested over a similar window. It also gives vision and reading measures time to separate. The cost is a long wait, and about 69 of every 100 people here stayed the course.
No, and nothing available today does. Every therapy under study here aims at slowing further loss, not rebuilding retinal cells that are gone. In SAGA both groups lost letters of vision over two years, and the only question was whether one lost fewer. If you want improvement rather than protection, low-vision rehabilitation, magnification and better lighting will do more for you now than any drug in development.
More Questions About an Oral Pill for Geographic Atrophy
Not at the moment. The registry lists the geographic atrophy study as completed, and the gildeuretinol studies now enrolling are in Stargardt disease, a different, inherited condition. That could change if the sponsor starts a new trial, so ask your retina specialist at each visit and check the registry yourself. If you find a study, bring the listing to your appointment.
The evidence is weaker than many people assume. An analysis of imaging from more than 1,200 untreated eyes in two geographic atrophy trials found no significant benefit of AREDS or AREDS2 supplements on how fast the atrophy grew, and the investigators said a randomized study would be needed to settle it. The formulas still have a role earlier, in intermediate AMD. Ask your eye doctor which stage you are at.
It is your sharpness of sight measured on a dimmed eye chart, standing in for how you see at dusk, in a restaurant, or in a dim hallway. People with this condition often read a normal chart well in bright light while struggling badly in low light, so the measure captures what standard testing misses. It matters here because that is where the largest difference appeared.
Nobody can promise one. The published report concluded that the exploratory findings support further evaluation in adequately powered trials, the usual language before a sponsor decides whether to commit. The active late-stage work listed on the registry is in Stargardt disease. Watching the registry beats press coverage, which tends to report the encouraging half of a mixed result.
- How large is the atrophy in each of my eyes, and how fast has it grown on my scans?
- Am I a candidate for either approved injection, and what would you expect it to do for me?
- What are the specific risks of those injections for my eyes and my history?
- Are any geographic atrophy studies enrolling near me that I would qualify for?
- Which supplements make sense at my stage, and are any of mine unnecessary?
- How often should I be seen, and what change at home should make me call sooner?
- Ophthalmology Retina (peer-reviewed), via PubMed (2026). Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The Study of ALK-001 in Geographic Atrophy (SAGA) Randomized Clinical Trial.
- American Academy of Ophthalmology (EyeSmart patient information) (2024). What to Know About Syfovre and Izervay for Geographic Atrophy.
- American Academy of Ophthalmology (EyeSmart patient information) (2025). Geographic Atrophy: Causes, Symptoms, Treatment.
- Journal of Biological Chemistry (laboratory and animal study), via PubMed (2011). Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents.
- U.S. Food and Drug Administration product label, via DailyMed (National Library of Medicine) (2025). SYFOVRE (pegcetacoplan injection) prescribing information: indication, dosing, warnings and precautions, and most common adverse reactions.
- U.S. Food and Drug Administration product label, via DailyMed (National Library of Medicine) (2026). IZERVAY (avacincaptad pegol intravitreal solution) prescribing information: indication, dosing, warnings and precautions, and most common adverse reactions.
- ClinicalTrials.gov (U.S. National Library of Medicine) (2025). Phase 2/3 Study of ALK-001 in Geographic Atrophy (SAGA), NCT03845582: study record and posted results, including the adverse-event tables.
- ClinicalTrials.gov (U.S. National Library of Medicine) (2026). Study of ALK-001 on the Progression of Stargardt Disease, NCT07419334: phase 3 study record and recruitment status.
- ClinicalTrials.gov (U.S. National Library of Medicine) (2026). ALK-001 (gildeuretinol) intervention search on the public trials registry: the full list of registered study records and their recruitment statuses.
- MedlinePlus Medical Encyclopedia, U.S. National Library of Medicine (2025). Vitamin A (MedlinePlus Medical Encyclopedia): what too much vitamin A does, including build-up in the body and birth defects from large doses in pregnancy.
- National Eye Institute (NEI), National Institutes of Health (2025). Nutritional Supplements for Age-Related Macular Degeneration (the AREDS and AREDS2 formulas).
- National Eye Institute (NEI), National Institutes of Health (2025). Age-Related Macular Degeneration (AMD): symptoms, risk factors, diagnosis and treatment.
- Cochrane Database of Systematic Reviews, via PubMed (2019). Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.